$LNAI News

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Why Did LNAI Stock Soar Over 100% In Pre-Market Trading Today?

Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session

Lunai Bioworks Regains Nasdaq Compliance

Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration

Lunai Bioworks' BioSymetrics And BrainStorm Therapeutics Announce Strategic Collaboration And LOI Integrating AI Discovery, Human Brain Organoid Modeling, And In Vivo Validation To Generate Differentiated Neurology Assets For Pharmaceutical Partnering And Development

LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT

Lunai Bioworks Inc. - Common Stock Q3 EPS $(0.10), Sales $20.942K

Lunai Bioworks Approves Reverse Stock Split At Ratio Of 1-For-3 To 1-For-30

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

Lunai Bioworks' Subsidiary Inks Letter Of Intent With Geneial Over Strategic Partnership In Rare Neurological Disorders

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion

Lunai Bioworks shares are trading higher after the company announced it entered into a a revenue-generating, commercial defense-focused collaboration with a specialized biotechnology partner to support the development of an advanced AI-enabled platform for chemical threat assessment.

Lunai Bioworks shares are trading higher after the company announced it entered into a a revenue-generating, commercial defense-focused collaboration with a specialized biotechnology partner to support the development of an advanced AI-enabled platform for chemical threat assessment.

Lunai Bioworks' BioSymetrics Launches AI-Enabled Chemical Threat Detection Collaboration, Advancing Dual-Use Biodefense Through Commercial Engagement

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications

What's Behind The Jump In Lunai Bioworks Stock?

Lunai Bioworks shares are trading higher after the company announced that it will acquire blood-brain barrier delivery technology and central nervous system Alzheimer's drug assets from the Clemann Group for $20 million.

Lunai Bioworks Executes $20M Transaction To Acquire Blood-Brain Barrier Delivery Technology And Central Nervous System Alzheimer's Drug Assets From Clemann Group